Puerto Rico vs South-East Asia (WHO region): Treatment success rate for patients treated for MDR-TB
Puerto Rico
100.0%
in 2020
South-East Asia (WHO region)
77.0%
in 2022
Puerto Rico rank
1st
South-East Asia (WHO region) rank
2nd
Treatment success rate for patients treated for MDR-TB over time
- Puerto Rico
- South-East Asia (WHO region)
How they compare
Puerto Rico currently reports 100.0% against 77.0% in South-East Asia (WHO region), a difference of 23.0%.
That makes Puerto Rico's figure about 1.3 times South-East Asia (WHO region)'s.
The two have swapped places 3 times across 9 shared years of data; in 2006 it was South-East Asia (WHO region) ahead.
Puerto Rico ranks 1st and South-East Asia (WHO region) ranks 2nd of 163 countries.
Across the 3 decades both report, Puerto Rico averaged higher in 2 and South-East Asia (WHO region) in 1.
Head to head by decade
| Decade | Puerto Rico | South-East Asia (WHO region) | Difference | Ahead |
|---|---|---|---|---|
| 2000s | 33.3% | 62.7% | 29.3% | South-East Asia (WHO region) |
| 2010s | 73.4% | 51.8% | 21.6% | Puerto Rico |
| 2020s | 100.0% | 69.0% | 31.0% | Puerto Rico |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher treatment success rate for patients treated for mdr-tb, Puerto Rico or South-East Asia (WHO region)?
- Puerto Rico, at 100.0% against 77.0% in South-East Asia (WHO region) as of 2020.
- What is the difference in treatment success rate for patients treated for mdr-tb between Puerto Rico and South-East Asia (WHO region)?
- 23.0%, with Puerto Rico ahead.
- How many years of comparable data are there for Puerto Rico and South-East Asia (WHO region)?
- 9 years are reported by both, from 2006 to 2020.
- How do Puerto Rico and South-East Asia (WHO region) rank globally for treatment success rate for patients treated for mdr-tb?
- Puerto Rico ranks 1st and South-East Asia (WHO region) ranks 2nd of 163 countries.
- Where does this data come from?
- World Health Organization, Global Health Observatory, published as Treatment success rate for patients treated for MDR-TB (%). Statizoid refreshes it automatically from the source and publishes the full history for both places.